Amgen’s Q3 2026 review reveals modest growth from Repatha, Imdelltra, and Uplizna, while outlining strategic moves for MariTide and future biotech wins.
Amgen’s Q3 results show steady revenue growth from its cholesterol and lung‑cancer drugs while advancing a promising weight‑loss candidate, balancing cash flow, R&D spend, and debt in a competitive biotech market.
Fresenius partners with WuXi Biologics to add 37 biosimilar candidates, doubling its biopharma pipeline, targeting high‑margin oncology and eye disease, and securing first‑to‑market control for robust ROI.
Amgen strengthens governance with ex‑Yum! CEO David Gibbs, while its oncology, rare‑disease, and cardiovascular pipeline shows breakthrough trial results and FDA progress.
Roche’s divarasib shows a 6‑month overall‑survival edge over sotorasib and adagrasib in KRAS G12C NSCLC, offering a promising, safer option and new market‑share opportunities.
Amgen’s bispecific Imdelltra + Imfinzi boosts overall survival in extensive‑stage small cell lung cancer by 56%, adding 8 months and redefining first‑line therapy.